cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2020-2592cardiovascular-2592Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯCLINIC AND PHARMACOTHERAPYСовременный взгляд на проблему фармакотерапии хронической венозной недостаточности препаратами микронизированной очищенной флавоноидной фракцииModern view on the therapy of chronic venous insufficiency with micronized purified flavonoid fractionhttps://orcid.org/0000-0002-5990-8561КургинянХ. М.KurginyanH. M.

Хачатур Михаилович Кургинян - заместитель главного врача КДЦ по хирургии ФГБУ НМИЦ терапии и профилактической медицины

Москва

bzhishk@list.ruhttps://orcid.org/0000-0001-8295-9458РаскинВ. В.RaskinV. V.

Владимир Вячеславович Раскин - ведущий флеболог

Москва

vr25000@gmail.comФГБУ “Национальный медицинский исследовательский центр терапии и профилактической медицины” Минздрава РоссииNational Medical Research Center for Therapy and Preventive MedicineМедицинский инновационный флебологический центрMedical innovative phlebological center20200309202019425922592Copyright © Кургинян Х.М., Раскин В.В., 20202020Кургинян Х.М., Раскин В.В.Kurginyan H.M., Raskin V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2592

Высокая распространенность варикозной болезни отмечена в многочисленных популяционных исследованиях. В настоящее время разработаны протоколы лечения пациентов с варикозной болезнью для различных стадий хронической венозной недостаточности. Тем не менее, у значительного числа пациентов не удается полностью купировать симптомы венозной недостаточности, несмотря на применение современных лекарственных средств, компрессионных изделий, хирургических и иных вмешательств. Статья посвящена анализу современных клинических эффектов и исследований препаратов микронизированной флавоноидной очищенной фракции. Разработка современных препаратов для лечения хронических заболеваний вен представляет собой важное направление в развитии медицины. Формирование пула отечественных лекарственных средств является приоритетным направлением развития фармацевтической промышленности Российской Федерации. В обзоре представлены данные по исследованию препарата Детравенол, который представляет собой российский комбинированный препарат диосмина и гесперидина (в составе микронизированной очищенной флавоноидной фракции).

The high prevalence of varicose veins has been established in numerous population studies. Currently, guidelines have been developed for the treatment of patients with varicose veins for various stages of chronic venous insufficiency. Nevertheless, despite the use of modern drugs, leg compression, surgical and other interventions, it is not possible to completely reverse the symptoms of venous insufficiency. The article is devoted to the analysis of micronized flavonoid purified fraction. The development of modern drugs for chronic venous diseases is an important direction in medicine. The creation of a drug pool manufactured InRussiais a priority in the development of the country’s pharmaceutical industry. The review presents data on the study of Detravenol (Russia), which is a combination of diosmin and hesperidin (micronized purified flavonoid fraction).

тромбозварикозное расширение венпосттромботическая болезньсосудистые заболеванияфакторы рискавенотоникиэндотелийchronic venous insufficiencyvaricose veinsvenotonic agentsphlebotonicsmicronized purified flavonoid fractionDetravenolReferencesКириенко А.И., Богачев В.Ю., Гаврилов С.Г., Золотухин И.А., Голованова О.В., Журавлева О.В., Брюшков А.Ю. Хронические заболевания вен нижних конечностей у работников промышленных предприятий Москвы (результаты эпидемиологического исследования). Ангиология и сосудистая хирургия. 1995;10(1):77-86Kirienko A.I., Bogachev V.Yu., Gavrilov S.G., Zolotukhin I.A., Golovanova O.V., Zhuravleva O.V., Bryushkov A.Yu. Chronic diseases of the veins of the lower extremities in workers of industrial enterprises in Moscow (results of an epidemiological study). Angiology and vascular surgery. 1995; 10 (1): 77-86Мазайшвили К.В., Чен В.И. Распространенность хронических заболеваний вен нижних конечностей в Петропавловске-Камчатском. Флебология. 2008;2(4):52-54Mazayshvili K.V., Chen V.I. The prevalence of chronic diseases of the veins of the lower extremities in Petropavlovsk-Kamchatsky. Phlebology. 2008; 2 (4): 52-54Савельев В.С., Кириенко А.И., Золотухин И.А., Селиверстов С.Е. Проспективное обсервационное исследование СПЕКТР: регистр пациентов с хроническими заболеваниями вен нижних конечностей. Флебология. 2012;6(1):4-9.Saveliev V.S., Kirienko A.I., Zolotukhin I.A., Seliverstov S.E. SPECTRUM prospective observational study: a register of patients with chronic lower limb vein diseases. Phlebology. 2012; 6 (1): 4-9.Travers JP, Brookes CE, Evans J, Baker DM, Kent C, Makin GS, et al. Assessment of wall structure and composition of varicose veins with reference to collagen, elastin and smooth muscle content. Eur J Vasc Endovasc Surg 1996;11:230-7Travers JP, Brookes CE, Evans J, Baker DM, Kent C, Makin GS, et al. Assessment of wall structure and composition of varicose veins with reference to collagen, elastin and smooth muscle content. Eur J Vasc Endovasc Surg 1996; 11: 230-7Wali MA, Eid RA. Changes of elastic and collagen fibers in varicose veins. Int Angiol 2002;21:337-43.Wali MA, Eid RA. Changes of elastic and collagen fibers in varicose veins. Int Angiol 2002; 21: 337-43.Jacob MP, Badier-Commander C, Fontaine V, Benazzoug Y, Feldman L, Michel JB. Extracellular matrix remodeling in the vascular wall. Pathol Biol (Paris) 2001;49:326-32.Jacob MP, Badier-Commander C, Fontaine V, Benazzoug Y, Feldman L, Michel JB. Extracellular matrix remodeling in the vascular wall. Pathol Biol (Paris) 2001; 49: 326-32.Российские клинические рекомендации по диагностике и лечению хронических заболеваний вен. Флебология. 2018. №3. с. 146-240Russian clinical guidelines for the diagnosis and treatment of chronic venous diseases. Phlebology. 2018. No3. with. 146-240Sindrup JH, Avnstorp C, Steenfos HH, Kristensen JK. Transcutaneous PO2 and laser Doppler blood flow measurements in 40 patients with venous leg ulcers. Acta Derm Venereol 1987;67:160-3Sindrup JH, Avnstorp C, Steenfos HH, Kristensen JK. Transcutaneous PO2 and laser Doppler blood flow measurements in 40 patients with venous leg ulcers. Acta Derm Venereol 1987; 67: 160-3Bollinger A, Fagrell B. Clinical capillaroscopy: a guide to its use in clinical research and practice. Bern, Switzerland.: Hogrefe and Huber, 1990Bollinger A, Fagrell B. Clinical capillaroscopy: a guide to its use in clinical research and practice. Bern, Switzerland .: Hogrefe and Huber, 1990Bollinger A, Jager K, Sgier F, Seglias J. Fluorescence microlymphography. Circulation 1981;64:1195-200Bollinger A, Jager K, Sgier F, Seglias J. Fluorescence microlymphography. Circulation 1981; 64: 1195-200Higley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol 1995;132:79-85.Higley HR, Ksander GA, Gerhardt CO, Falanga V. Extravasation of macromolecules and possible trapping of transforming growth factor-beta in venous ulceration. Br J Dermatol 1995; 132: 79-85.Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B, Giannoukas AD, Lugli M, Maleti O, Myers K, Nelzén O, Partsch H, Perrin M. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018 Jun;37(3):181-254. doi: 10.23736/S0392-9590.18.03999-8.Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B, Giannoukas AD, Lugli M, Maleti O, Myers K, Nelzén O, Partsch H, Perrin M. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018 Jun; 37 (3): 181-254. doi: 10.23736 / S0392-9590.18.03999-8.Lurie F. Advanced Stages of Chronic Venous Disease: Evolution of Surgical Techniques and Advantages of Associated Medical Treatment. Adv Ther. 2020 Feb;37(Suppl 1):6-12. doi: 10.1007/s12325-019-01216-w. Epub 2020 Jan 24.Lurie F. Advanced Stages of Chronic Venous Disease: Evolution of Surgical Techniques and Advantages of Associated Medical Treatment. Adv Ther. 2020 Feb; 37 (Suppl 1): 6-12. doi: 10.1007 / s12325-019-01216-w. Epub 2020 Jan 24.Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg 2000;31:456-61.Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg 2000; 31: 456-61.He P. Leucocyte/endothelium interactions and microvessel permeability: coupled or uncoupled? Cardiovasc Res 2010;87:281-90He P. Leucocyte / endothelium interactions and microvessel permeability: coupled or uncoupled? Cardiovasc Res 2010; 87: 281-90Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. Angiology 1997;48:391-9.Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia / reperfusion in the hamster cheek pouch. Angiology 1997; 48: 391-9.Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010;87:262-71.Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010; 87: 262-71.Shoab SS, Scurr JH, Coleridge-Smith PD. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study. Eur J Vasc Endovasc Surg 1999;18:334-8.Shoab SS, Scurr JH, Coleridge-Smith PD. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study. Eur J Vasc Endovasc Surg 1999; 18: 334-8.Chen WY, Rogers AA. Recent insights into the causes of chronic leg ulceration in venous diseases and implications on other types of chronic wounds. Wound Repair Regen 2007;15:434-49.Chen WY, Rogers AA. Recent insights into the causes of chronic leg ulceration in venous diseases and implications on other types of chronic wounds. Wound Repair Regen 2007; 15: 434-49.Pappas PJ, You R, Rameshwar P, Gorti R, DeFouw DO, Phillips CK, et al. Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-beta1 gene expression and protein production. J Vasc Surg 1999;30:1129-45.Pappas PJ, You R, Rameshwar P, Gorti R, DeFouw DO, Phillips CK, et al. Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-beta1 gene expression and protein production. J Vasc Surg 1999; 30: 1129-45.Le Devehat C, Khodabandehlou T, Vimeux M, Kempf C. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. Int J Microcirc Clin Exp 1997;17(Suppl 1):27-33.Le Devehat C, Khodabandehlou T, Vimeux M, Kempf C. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. Int J Microcirc Clin Exp 1997; 17 (Suppl 1): 27-33.Langer RD, Ho E, Denenberg JO, Fronek A, Allison M, Criqui MH. Relationships between symptoms and venous disease: the San Diego population study. Arch Intern Med 2005;165:1420-4Langer RD, Ho E, Denenberg JO, Fronek A, Allison M, Criqui MH. Relationships between symptoms and venous disease: the San Diego population study. Arch Intern Med 2005; 165: 1420-4Jawien A, Grzela T, Ochwat A. Prevalence of chronic venous insufficiency in men and women in Poland: multicentre cross-sectional study in 40,095 patients. Phlebology 2003;18:110-22.Jawien A, Grzela T, Ochwat A. Prevalence of chronic venous insufficiency in men and women in Poland: multicentre cross-sectional study in 40,095 patients. Phlebology 2003; 18: 110-22.Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez QF. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012;31:105-15.Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez QF. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol 2012; 31: 105-15.Vincent JR, Jones GT, Hill GB, van Rij AM. Failure of microvenous valves in small superficial veins is a key to the skin changes of venous insufficiency. J Vasc Surg 2011;54:62S-9S.Vincent JR, Jones GT, Hill GB, van Rij AM. Failure of microvenous valves in small superficial veins is a key to the skin changes of venous insufficiency. J Vasc Surg 2011; 54: 62S-9S.Lugli M, Maleti O, Iabichella ML, Perrin M. Investigation of non-saphenous veins in C0S patients. Int Angiol. 2018;37(2):169–75.Lugli M, Maleti O, Iabichella ML, Perrin M. Investigation of non-saphenous veins in C0S patients.2018;37(2):169–75.Mansilha, A. (2020). Early Stages of Chronic Venous Disease: Medical Treatment Alone or in Addition to Endovenous Treatments. Advances in Therapy, 37(S1), 13–18. doi:10.1007/s12325-019-01217-9Mansilha, A. (2020). Early Stages of Chronic Venous Disease: Medical Treatment Alone or in Addition to Endovenous Treatments. Advances in Therapy, 37(S1), 13–18. doi:10.1007/s12325-019-01217-9Tsukanov YT, Tsukanov AY. Diagnosis and treatment of situational great saphenous vein reflux in daily medical practice. Phlebolymphology. 2017;24(3):144–51.Tsukanov YT, Tsukanov AY. Diagnosis and treatment of situational great saphenous vein reflux in daily medical practice. Phlebolymphology. 2017;24(3):144–51.Lee AJ, Robertson LA, Boghossian SM, et al. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord. 2015;3(1):18–26. doi: 10.1016/j.jvsv.2014.09.008Lee AJ, Robertson LA, Boghossian SM, et al. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord. 2015;3(1):18–26. doi: 10.1016/j.jvsv.2014.09.008Veverkova´ L, Kalacˇ J, Jedlicˇka V, Wechsler J. Analysis of the various procedures used in great saphenous vein surgery in the Czech Republic and benefit of Daflon 500 mg to postoperative symptoms. Phlebolymphology. 2006;13(4):193–9.Veverkova´ L, Kalacˇ J, Jedlicˇka V, Wechsler J. Analysis of the various procedures used in great saphenous vein surgery in the Czech Republic and benefit of Daflon 500 mg to postoperative symptoms. Phlebolymphology. 2006;13(4):193–9.Saveljev VS, Pokrovsky AV, Kirienko AI, Bogachev VY, Zolotukhin IA, Sapelkin SV. Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE). Phlebolymphology. 2008;15(2):45–51.Saveljev VS, Pokrovsky AV, Kirienko AI, Bogachev VY, Zolotukhin IA, Sapelkin SV. Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE). Phlebolymphology. 2008;15(2):45–51.Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized doubleblind placebo-controlled trials. Int Angiol. 2018;37(2):143–54 (Epub 2018/02/02).Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized doubleblind placebo-controlled trials. Int Angiol. 2018;37(2):143–54 (Epub 2018/02/02).Пономарев Э.А., Стрепетов Н.Н., Сотников И.Е., Васильев С.В., Арнаутов В.С., Касаткина И.С., Бухтенков А.В. Применение препарата детравенол при лечении хронической венозной недостаточности. Ангиология и сосудистая хирургия. 2020 №2 (в печати)Ponomarev E.A., Strepetov N.N., Sotnikov I.E., Vasiliev S.V., Arnautov V.S., Kasatkina I.S., Bukhtenkov A.V. The use of the drug detravenol in the treatment of chronic venous insufficiency. Angiology and vascular surgery. 2020 ı2 (in print)Nicolaides, A. N. (2020). The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease. Advances in Therapy. doi:10.1007/s12325-019-01218-8Nicolaides, A. N. (2020). The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease. Advances in Therapy. doi: 10.1007 / s12325-019-01218-8Nicolaides, A. N. (2020). The Most Severe Stage of Chronic Venous Disease: An Update on the Management of Patients with Venous Leg Ulcers. Advances in Therapy. doi:10.1007/s12325-020-01219-yNicolaides, A. N. (2020). The Most Severe Stage of Chronic Venous Disease: An Update on the Management of Patients with Venous Leg Ulcers. Advances in Therapy. doi: 10.1007 / s12325-020-01219-y

The authors declare that there are no conflicts of interest present.